Parenteral Treprostinil Shows Efficacy in Pediatric PAH, Meta-Analysis Confirms

A systematic review and meta-analysis evaluated the efficacy and safety of parenteral treprostinil in pediatric pulmonary arterial hypertension (PAH). The study included a comprehensive literature search from January 2000 to April 2024, identifying 32 studies with 766 pediatric PAH patients treated with parenteral prostacyclins, of which 649 received treprostinil. The meta-analysis focused on five publications encompassing 143 treprostinil-naïve patients. Despite the absence of randomized controlled trials, the meta-analysis revealed statistically significant improvements in PAH-relevant efficacy endpoints, indicating a clear treatment benefit of parenteral treprostinil. The findings suggest that, based on the available data, parenteral treprostinil is both effective and safe for treating pediatric PAH. However, the reliance on cohort studies and retrospective data highlights the need for further research to strengthen the evidence base.

Pulmonary arterial hypertension (PAH) can be a challenging condition for children, often requiring specialized treatment. A recent systematic review looked at the effectiveness and safety of parenteral treprostinil, a medication that could make a difference for these young patients. The review included 32 studies with 766 children treated with parenteral prostacyclins, and specifically focused on 143 children who had not previously received treprostinil. While there were no randomized controlled trials, the data clearly showed that parenteral treprostinil offers a treatment benefit for children with PAH. The findings were supported by statistically significant results in the meta-analysis, indicating that this medication is not only effective but also safe. For families dealing with pediatric PAH, this information is crucial, as it highlights a potential treatment that could improve their child's health and quality of life.